This week Dr. Evan Loh, Paratek CEO, returns to Off the

Shelf to share the latest in the biopharmaceutical company’s partnership with

the Biomedical Advanced Research and Development Authority’s (BARDA’s) 

Project BioShield. 

Paratek’s antibiotic, NUZYRA (omadacycline) has been

designated “an essential” medicine by the FDA, and Loh provides an update

on the progress made in onshoring of manufacturing of NUZYRA, from the

production of API through finished drug product for both IV and oral

formulations. 

Loh shares the journey to domestic manufacturing, highlighting the critical role Paratek’s public-private partnership with BARDA played in developing manufacturing capability.

Antimicrobial resistance (AMR) along with biological threat actors are continuing and growing threat and Loh discusses the current environment and the key policy considerations in

combatting these and other healthcare threats. 

Finally, Loh talks about the potential that the results from the successful development of treatments through public-partnerships have the potential to be leveraged to support/protect

the warfighter.    

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.